Tumor antigen-derived peptide-Major Histocompatibility Complex class II complex (pMHCII complex)

Tumor antigen-derived peptides presented on MHC class II molecules represent a critical interface in the immune system's ability to recognize and eliminate cancer. These complexes are primarily found on the surface of professional antigen-presenting cells (APCs), such as dendritic cells and macrophages, which internalize tumor debris and process it into short peptide fragments for display. Unlike MHC class I, which presents to CD8+ cytotoxic T-cells, the MHC class II complex is recognized by the T-cell receptor (TCR) of CD4+ helper T-cells. This interaction is essential for orchestrating a robust and sustained antitumor response, as CD4+ T-cells provide necessary signals for B-cell activation, CD8+ T-cell memory formation, and the recruitment of innate immune effectors. In the context of oncology, these complexes are targeted through various immunotherapeutic strategies, including neoantigen vaccines designed to increase their density on APCs and engineered TCR-T therapies that specifically bind the pMHCII complex. However, therapeutic efficacy can be challenged by tumor-mediated downregulation of MHC molecules or the presence of an immunosuppressive microenvironment that inhibits T-cell activation.

Other names

Tumor-associated antigen-MHC II complexNeoantigen-MHC II complexpMHCIIMHC class II-restricted tumor antigenHLA class II-peptide complex

Drugs targeting these complexes typically act by either providing the peptide (vaccines) to be loaded onto MHC II by antigen-presenting cells or by using engineered receptors (TCRs or TCR-like antibodies) to recognize the specific peptide-MHC II complex on the cell surface, thereby triggering a targeted immune response against tumor cells or activating helper T-cells to orchestrate a broader immune attack.